Health Officials Tackle State‑Federal Clash Over Clinical AI
Officials are racing to smooth the path for AI that can write prescriptions as states and the federal government grapple with overlapping authority.
Exciting times ahead for AI in medicine!
Health officials are working behind the scenes to resolve a brewing clash between state regulators and the federal government over artificial‑intelligence tools that can perform clinical work such as writing prescriptions.
The Trump administration has taken steps to lessen the regulatory load on companies developing health‑care AI and has introduced new mechanisms to fund the technology.
However, a core issue remains: states oversee the practice of medicine and issue licenses to doctors and other clinicians, while the Food and Drug Administration regulates medical devices.
If AI systems carry out tasks like prescribing without direct human supervision, those products could fall under the FDA’s jurisdiction rather than state medical boards.
This overlap threatens to create a regulatory logjam just as more states look to pilot AI in clinical settings.
Stakeholders hope that clarifying the boundaries between state and federal oversight will keep the momentum going for AI‑driven health innovations.
